Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Duke University
City of Hope Medical Center
Eli Lilly and Company
Novartis
Sensei Biotherapeutics, Inc.
Compugen Ltd
Tempus AI
NextCure, Inc.